These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 20083823)
1. ACP Journal Club. One or two 7.5-microg doses of MF59-adjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in adults within 21 days. Granwehr B Ann Intern Med; 2010 Jan; 152(2):JC1-8, JC1-9. PubMed ID: 20083823 [No Abstract] [Full Text] [Related]
2. ACP Journal Club. A 15-microg dose of unadjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in healthy adults within 21 days. Granwehr B Ann Intern Med; 2010 Jan; 152(2):JC1-9, JC1-8. PubMed ID: 20083824 [No Abstract] [Full Text] [Related]
3. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847 [TBL] [Abstract][Full Text] [Related]
4. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131 [TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638 [TBL] [Abstract][Full Text] [Related]
7. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
9. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Tsai TF; Crucitti A; Nacci P; Nicolay U; Della Cioppa G; Ferguson J; Clemens R Scand J Infect Dis; 2011 Sep; 43(9):702-6. PubMed ID: 21534891 [TBL] [Abstract][Full Text] [Related]
10. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971 [TBL] [Abstract][Full Text] [Related]
11. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662 [TBL] [Abstract][Full Text] [Related]
12. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282 [TBL] [Abstract][Full Text] [Related]
14. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530 [TBL] [Abstract][Full Text] [Related]
15. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049 [TBL] [Abstract][Full Text] [Related]
16. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892 [TBL] [Abstract][Full Text] [Related]
18. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699 [TBL] [Abstract][Full Text] [Related]
19. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. Tsai T; Kyaw MH; Novicki D; Nacci P; Rai S; Clemens R Vaccine; 2010 Feb; 28(7):1877-80. PubMed ID: 19969117 [TBL] [Abstract][Full Text] [Related]
20. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]